NCT05165264View on ClinicalTrials.gov

A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Gastric Cancer
Trial Locations (1)

20246

Local Institution - 0001, Hamburg

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05165264 - A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer | Biotech Hunter | Biotech Hunter